3 yr interim RELIANCE study analysis shows long-term CAN tx is safe and effective in CAPS regardless of the underlying mutation and TRAPS. Abs 0812 #ACR22 @RheumNow https://t.co/pgSq1IICJK and https://t.co/Y2NUpgXGPL https://t.co/j9DMFF7V8S
Links:
3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-asso…
http://ow.ly/iUHC50Lxs6H
Canakinumab in Patients with Tumor Necrosis Factor Receptor-associated Periodic…
https://acrabstracts.org/abstract/canakinumab-in-patients-with-tumor-necrosis-f…
13-11-2022
